Achillion Pharmaceuticals (ACHN)
Achillion Pharmaceuticals R&D Expense: 8.942M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ACHN R&D Expense Rankings
| Overall | 34th percentile | 1152 of 1764 |
| Sector | 37th percentile | 260 of 413 in Healthcare |
| Industry | 40th percentile | 90 of 150 in Biotechnology |
ACHN R&D Expense Range, Past 5 Years
| Minimum | 3.96M | Mar 2010 |
| Maximum | 9.937M | Dec 2011 |
| Average | 6.157M |
About R&D Expense
R&D expenses are a line item from many companies' income statements.
R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.
Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.
An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More
You may also be interested in these ACHN related companies
ACHN News
$ACHN - http://stks.co/3yzI http://stks.co/3yzJ Updated chart. $7.40 trigger still intact.
about 2 days ago by Ammeo
about 2 days ago by Ammeo
$ACHN had a huge fall.....and has consolidated nicely. Should move up very well from here on its news. HF in here now too
about 6 days ago by taketheplunge
about 6 days ago by taketheplunge
News related to $ACHN, currently -5.6% since open: 'Achillion gets FDA incentives for hepatitis C drug' http://stks.co/3pmu
about 12 days ago by TradeBot
about 12 days ago by TradeBot
$ACHN up 7% in pre today but $IDIX still the better co. and both heating back up again lately while everyone distracted by $FB
about 12 days ago by QR_Winner
about 12 days ago by QR_Winner
EBR: Watchlist/worksheet/4 Trading Ideas: $OPTR $ACHN $BEAM $V http://stks.co/3pOI
about 12 days ago by TheEquitiesRoom
about 12 days ago by TheEquitiesRoom
ACH-3102 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C
May 15, 7:02AM Benzinga
May 15, 7:02AM Benzinga
@WalkenTalken nailed this $soda. For his next trick maybe he can endorse some $ACHN for me. Find out his take on $PCLN $MCP
about 18 days ago by HTB_Krull
about 18 days ago by HTB_Krull
Achillion Advances Second Generation Pan-Genotypic NS5A Inhibitor, ACH-3102, Into Clinical Development
May 09, 7:00AM GlobeNewswire
May 09, 7:00AM GlobeNewswire
$achn now green too......what is going on in hep c world? $achn $idix
about 19 days ago by taketheplunge
about 19 days ago by taketheplunge
UPDATE: UBS Investment Research Upgrades Achillion to Neutral; Balanced Risk/Reward
May 07, 12:55PM Benzinga
May 07, 12:55PM Benzinga
RT @AaronM @Bleedblue sorry about that confusion.. I heart $ARNA.. $ACHN blows < stop reading AF's columns and go long bud!>
about 26 days ago by Bleedblue
about 26 days ago by Bleedblue
Baird Maintains an 'Outperform' on Achillion Pharmaceuticals (ACHN); Reassuring Clarification on '1625
Apr 23, 2:22PM Street Insider
Apr 23, 2:22PM Street Insider
Wells Fargo Maintains an 'Outperform' on Achillion Pharmaceuticals (ACHN); A Few Hiccups, But Expect Positive N-T Data
Apr 23, 12:27PM Street Insider
Apr 23, 12:27PM Street Insider
Achillion (ACHN) Updates on EQT Data from Segment 2 of ACH-1625 Phase 2a
Apr 23, 9:27AM Street Insider
Apr 23, 9:27AM Street Insider
Pharmaceutical Companies Look to Biotech Industry to Combat Losses From Expiring Patents
Apr 23, 8:20AM Marketwire
Apr 23, 8:20AM Marketwire
JMP Securities Downgrades Achillion Pharmaceuticals (ACHN) to Market Perform
Apr 23, 8:08AM Street Insider
Apr 23, 8:08AM Street Insider
Achillion (ACHN) Presents Strong Data from ACH-1625 Phase 2a; Safety Profile Similar
Apr 23, 7:36AM Street Insider
Apr 23, 7:36AM Street Insider
Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C
Apr 21, 4:00AM GlobeNewswire
Apr 21, 4:00AM GlobeNewswire
Baird Reiterates an 'Outperform' on Achillion Pharmaceuticals (ACHN); Buy on Weakness
Apr 19, 4:29PM Street Insider
Apr 19, 4:29PM Street Insider
UPDATE - UBS Initiates Coverage on Achillion Pharma (ACHN) with a Neutral; All-Oral Combo Already Priced In
Apr 12, 10:57AM Street Insider
Apr 12, 10:57AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ACHN | 7.35 | +0.03 | +0.41% | 518.69M |
| ABB | 16.18 | -0.22 | -1.34% | 37.45B |
| ABAX | 32.56 | -0.02 | -0.06% | 706.23M |
| AB | 13.38 | -0.19 | -1.40% | 1.407B |
| AAXJ | 49.90 | -0.38 | -0.76% | |
| AAWW | 45.92 | -0.76 | -1.63% | 1.208B |
| AAV | 2.83 | -0.01 | -0.35% | 471.39M |
| AAU | 2.01 | -0.04 | -1.95% | 118.83M |
| AAPL | 562.29 | -3.03 | -0.54% | 524.26B |
| AAP | 73.67 | +0.74 | +1.01% | 5.373B |
